UNITED STATES

0001558370-22-010716.txt : 20220714 0001558370-22-010716.hdr.sgml : 20220714 20220714161552 ACCESSION NUMBER: 0001558370-22-010716 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20220531 FILED AS OF DATE: 20220714 DATE AS OF CHANGE: 20220714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BURZYNSKI RESEARCH INSTITUTE INC CENTRAL INDEX KEY: 0000724445 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 760136810 STATE OF INCORPORATION: DE FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23425 FILM NUMBER: 221083213 BUSINESS ADDRESS: STREET 1: 12000 RICHMOND AVE CITY: HOUSTON STATE: TX ZIP: 77082 BUSINESS PHONE: (713) 335-5697 MAIL ADDRESS: STREET 1: 9432 KATY FREEWAY CITY: HOUSTON STATE: TX ZIP: 77055 10-Q 1 bzyr-20220531x10q.htm 10-Q UNITED STATES

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended May 31, 2022


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-23425

Burzynski Research Institute, Inc.

(Exact name of Registrant as specified in its charter)


Delaware		76-0136810
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

9432 Katy Freeway, Suite 200, Houston, Texas 77055

(Address of principal executive offices)

(713) 335-5697

(Registrant’s telephone number)

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Trading Name of each exchange on which registered
None	BZYR	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻

Accelerated filer ◻

Non-accelerated filer ⌧

Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of June 30, 2022, 131,448,444 shares of the Registrant’s Common Stock were outstanding.

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

Form 10-Q

Table of Contents


PART I — FINANCIAL INFORMATION

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

Item 4.	Controls and Procedures	15

PART II — OTHER INFORMATION		15

Item 1.	Legal Proceedings	15

Item 6.	Exhibits	16

Table of Contents

Item 1.Financial Statements

BURZYNSKI RESEARCH INSTITUTE, INC.

BALANCE SHEETS

(UNAUDITED)


	May 31,		February 28,
	2022		2022
ASSETS

Current assets
Cash and cash equivalents	$	4,766	$	3,382
Prepaids		700		1,279

Total current assets		5,466		4,661

Total assets	$	5,466	$	4,661

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities
Accounts payable	$	13,925	$	—
Accrued liabilities		30,221		3,455

CURRENT AND TOTAL LIABILITIES		44,146		3,455

Commitments and contingencies

Stockholders’ equity (deficit)
Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of May 31, 2022 and February 28, 2022		131,449		131,449
Additional paid-in capital		125,900,091		125,708,240
Retained deficit		(126,070,220)		(125,838,483)

Total stockholders’ equity (deficit)		(38,680)		1,206

Total liabilities and stockholders’ equity (deficit)	$	5,466	$	4,661

See accompanying notes to financial statements.

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)


	Three Months Ended May 31,
	2022		2021
Operating expenses
Research and development	$	167,354	$	231,946
General and administrative		64,383		84,337

Total operating expenses		231,737		316,283

Operating loss		(231,737)		(316,283)

Loss before provision for income tax		(231,737)		(316,283)
Provision for income tax		—		—
Net loss	$	(231,737)	$	(316,283)

Earnings per share information:

Basic and diluted loss per common share	$	(0.00)	$	(0.00)

Weighted average number of common shares outstanding		131,448,444		131,448,444

See accompanying notes to financial statements.

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the Three Months Ended May 31, 2022

(UNAUDITED)


				Additional				Total
	Common Stock			Paid-in		Retained		Stockholders’
	Shares	Amount		Capital		Deficit		Equity (Deficit)
Balance at February 28, 2022	131,448,444	$	131,449	$	125,708,240	$	(125,838,483)	$	1,206

Cash contributed by S.R. Burzynski M.D., Ph.D.	—		—		40,517		—		40,517

FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	—		—		151,334		—		151,334

Net loss	—		—		—		(231,737)		(231,737)

Balance at May 31, 2022	131,448,444	$	131,449	$	125,900,091	$	(126,070,220)	$	(38,680)

See accompanying notes to financial statements.

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENT OF STOCKHOLDERS’ DEFICIT

For the Three Months Ended May 31, 2021

(UNAUDITED)


				Additional				Total
	Common Stock			Paid-in		Retained		Stockholders’
	Shares	Amount		Capital		Deficit		Deficit
Balance at February 28, 2021	131,448,444	$	131,449	$	124,684,535	$	(124,861,827)	$	(45,843)

Cash contributed by S.R. Burzynski M.D., Ph.D.	—		—		84,967		—		84,967

FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	—		—		215,926		—		215,926

Net loss	—		—		—		(316,283)		(316,283)

Balance at May 31, 2021	131,448,444	$	131,449	$	124,985,428	$	(125,178,110)	$	(61,233)

See accompanying notes to financial statements.

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Three Months Ended May 31,
	2022		2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(231,737)	$	(316,283)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		151,334		215,926

Changes in operating assets and liabilities
Prepaids		579		(521)
Accounts payable		13,925		(2,071)
Accrued liabilities		26,766		18,514

NET CASH USED BY OPERATING ACTIVITIES		(39,133)		(84,435)

CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital		40,517		84,967

NET CASH PROVIDED BY FINANCING ACTIVITIES		40,517		84,967

NET INCREASE IN CASH		1,384		532

CASH AT BEGINNING OF PERIOD		3,382		62

CASH AT END OF PERIOD	$	4,766	$	594

See accompanying notes to financial statements

Table of Contents

BURZYNSKI RESEARCH INSTITUTE, INC.

NOTES TO FINANCIAL STATEMENTS

NOTE A.

BASIS OF PRESENTATION

The financial statements of Burzynski Research Institute, Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer. These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital. Other funds received from Dr. Burzynski have also been reported as additional paid-in capital. Expenses related to Dr. Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements. Dr. Burzynski is the President, Chairman of the Board and owner of approximately 81.0% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.”

The Company and Dr. Burzynski have entered into various agreements as further described in Note B. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, the License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently own any patents or have licenses to any patents with respect to Antineoplastons.

The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of May 31, 2022 and February 28, 2022, results of operations for the three months ended May 31, 2022 and 2021, and cash flows for the three months ended May 31, 2022 and 2021. All adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022.

NOTE B.

ECONOMIC DEPENDENCY

The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit. Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding. Because the Company is entirely dependent upon the contributions for research provided by Dr. Burzynski under a research funding agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under a research funding agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.

Table of Contents

The Company is economically dependent on its funding through Dr. Burzynski’s medical practice. In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs. The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA. These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.

NOTE C.

STOCK OPTIONS AND WARRANTS

At May 31, 2022, the Company had one stock-based employee compensation plan, which is described below.

On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company. The options vested as follows:


		Vesting Date
400,000	options	September 14, 1996
100,000	options	June 1, 1997
100,000	options	June 1, 1998

The options are valid in perpetuity. None of the options have been exercised as of May 31, 2022.

The Company accounts for share-based payments to non-employees in accordance with the guidance provided by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.

Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to 10% of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of 2,000,000 shares of the Company’s Common Stock, exercisable at $0.10 per share with a ten year exercise period, with 1,000,000 shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining 1,000,000 shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The fair market value of the vested warrants as of the date of grant was measured using the Black-Scholes option pricing model and totaled approximately $160,000 or $0.16 per warrant. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants are currently outstanding and can still be exercised. As of May 31, 2022, none of the aforementioned vested warrants have been exercised.

NOTE D.

LOSS PER COMMON SHARE

The Company accounts for loss per share in accordance with FASB ASC 260, Earnings per Share. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three months ended May 31, 2022 and 2021, 1,600,000 warrants and stock options were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.

Table of Contents

NOTE E.

INCOME TAXES

The Company follows the provisions of FASB ASC 740, Income Taxes. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.

The Company recognizes interest and penalties as interest expense when they are accrued or assessed.

The federal income tax returns of the Company for 2020, 2019, and 2018 are subject to examination by the IRS, generally for three years after they are filed.

The actual provision for income tax for the three months ended May 31, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:


	Three Months Ended May 31,
	2022		2021
Expected expense (benefit)	$	(48,665)	$	(66,419)
Taxed directly to Dr. Burzynski		48,665		66,419
Nondeductible expenses and other adjustments		8,376		3,232
Change in valuation allowance		(8,376)		(3,232)
State taxes		—		—
Provision for income tax	$	—	$	—

At May 31, 2022, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $167,078. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has no historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.

As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of 80% of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to 80% of future taxable income according to the Act.

As of May 31, 2022, the Company has net operating loss carryforwards in the amount of $473,902 that will expire between 2026 and 2038, and $118,834 that will carryforward indefinitely, of which $78,948 applies to 100% of future taxable income and $39,886 applies to 80% of future taxable income.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following is a discussion of the financial condition of the Company as of May 31, 2022, and the results of operations comparing the three months ended May 31, 2022 and 2021. It should be read in conjunction with the financial statements and the notes thereto included elsewhere in this report and in conjunction with the Annual Report on Form 10-K for the year ended February 28, 2022.

Forward-Looking Statements

Certain matters discussed in this quarterly report, except for historical information contained herein, may constitute “forward-looking statements” that are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements provide current expectations of future events based on certain assumptions. These statements encompass information that does not directly relate to any historical or current fact and often may be identified with words such as “anticipates,” “believes,” “expects,” “estimates,” “intends,” “plans,” “projects” and other similar expressions. Management’s expectations and assumptions regarding Company operations and other future results are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements.

Introduction

The Company is primarily engaged as a research and development facility of drugs currently being tested for the use in the treatment of cancer, and provides consulting services. The Company’s clinical trial initiated in April 2016 for children and adults with Diffuse Intrinsic Pontine Glioma (DIPG) (protocol “BT-55”) is currently under full clinical hold.

On September 3, 2004, the FDA granted the Company’s request for “orphan drug designation” (“ODD”) for the Company’s Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma and, on October 30, 2008, the FDA granted the Company’s request for ODD for Antineoplastons (A10 and AS2-1 Antineoplaston) for the treatment of gliomas.

On January 13, 2009, the Company announced that the Company had reached an agreement with the FDA for the Company to move forward with a pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed diffuse, intrinsic brainstem gliomas (“DBSG”). The agreement was made under the FDA’s Special Protocol Assessment procedure, meaning that the design and planned analysis of the Phase III study of combination Antineoplastons A10 and AS2-1 plus radiation therapy (“RT”) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma (protocol “BT-52”), are acceptable to support a regulatory submission seeking new drug approval. However, the FDA placed a full clinical hold on IND 43742 regarding such Phase III clinical trial. Please see the section below entitled “Clinical Hold on Phase II and Phase III Clinical Trials.”

Clinical Hold on Phase II and Phase III Clinical Trials

In a letter dated June 25, 2012, the Company informed the FDA of a serious adverse event in which a patient who was receiving Antineoplastons developed grade 4 hypernatremia and subsequently died. The Antineoplaston-related hypernatremia was categorized by the investigator as possibly related to the study drug. Of the 2,297 patients who have received at least one dose of Antineoplastons, the serious adverse events (SAEs) which have been experienced are as follows: hemoglobin (grade 3: 0.13%; grade 4: 0.04%), extravasation (grade 3: 0.04%), pain (grade 3: 0.04%), fatigue (grade 3: 0.09%; grade 4: 0.04%), fever (grade 3: 0.09%), injection site reaction (grade 3: 0.04%), vomiting (grade 3: 0.09%), hypernatremia (grade 3: 0.09%; grade 4: 1.12%; grade 5: 0.26%), confusion (grade 3: 0.04%), seizure (grade 3: 0.04%), somnolence (grade 3: 0.35%; grade 4: 0.04%), pain: head/headache (grade 3: 0.09%) and pain: joint (grade 3: 0.04%).

Table of Contents

On July 30, 2012, the FDA placed a partial clinical hold for enrollment of new pediatric patients under single patient protocols or in any of the active Phase II or Phase III studies under IND 43742. The FDA imposed this partial clinical hold because, according to the FDA, insufficient information had been submitted by the Company to allow the FDA to determine whether the potential patient benefit justifies the potential risks of treatment use, and that the potential risks are not unreasonable in the context of the disease or condition to be treated. The FDA cited 21 C.F.R. § 312.42(b)(2)(i), 21 C.F.R. § 312.42(b)(1)(iv), and 21 C.F.R. § 312.42(b)(3)(i), as grounds for imposition of a clinical hold; and 21 C.F.R. § 312.305(a)(2), a criteria for expanded access use. The FDA advised the Company that until it resolved the matter to the FDA’s satisfaction, the Company could not enroll new pediatric patients in any protocol under such IND. The Company later notified the FDA in a September 24, 2012 letter that it was closing pediatric protocol BT-10 (under IND 43742) for enrollment effective September 25, 2012, and that it would also terminate the protocol once all active patients had completed the study. As of February 17, 2015, all patients discontinued treatment under protocol BT-10 and such protocol was closed as of March 10, 2015.

In a teleconference on January 9, 2013 between the FDA and the Company, followed by a letter of the same date, the FDA notified the Company that the agency was placing IND 43742 on partial clinical hold, due to a lack of a complete response to the issues raised by the FDA and what the FDA deemed a misleading, erroneous, and incomplete investigator brochure. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R. § 312.42(b)(1)(iii), as grounds for imposition of a clinical hold. The FDA further advised the Company that until it resolved the matter to the FDA’s satisfaction, that the Company could not enroll new adult or pediatric patients in any protocol under such IND. The FDA also placed protocol BT-52 on clinical hold due to what the FDA deemed to be an unreasonable and significant risk of illness or injury to human subjects. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R.§ 312.42(B)(1)(i), as grounds for imposition of a clinical hold. The FDA advised the Company that until it resolved the matter to the FDA’s satisfaction, the Company could not legally conduct the identified clinical study under such IND. In a teleconference with the FDA on September 16, 2013 and pursuant to the Company’s notification letter dated September 17, 2013, the Company notified the FDA that the proposed Phase III protocol BT-54 had been withdrawn from further consideration.

After several amendments to the IND which were reviewed by the FDA, the FDA concluded that BT-52 can be initiated and the partial clinical hold was removed by the FDA on June 20, 2014.

Additionally, the Company received IRB approval on February 4, 2015 for FDA reviewed protocol BT-55 open label, Phase II study of Antineoplaston A10 and AS2-1 in patients with a Diffuse Intrinsic Brainstem Glioma (DIPG) in five treatment groups based on patients age and prior treatment.

On April 20, 2016, the Company received a full clinical hold letter from the FDA based on FDA’s inspection of S.R. Burzynski’s manufacturing facility in March 2015. On April 27, 2016, the Company requested to change the full clinical hold to partial clinical hold to allow patient #1 to continue the Antineoplaston treatment according to protocol BT-55, since the patient was enrolled before the full clinical hold was imposed. Based on the FDA’s position regarding the Company’s request on April 27, 2016 and the Company’s teleconference with the FDA on May 3, 2016, the Company removed patient #1 from the study.

A temporary restraining order from the US District Court of Rhode Island allowed the resumption of patient #1’s Antineoplaston therapy on May 17, 2016. As a result of such temporary restraining order, a subsequent letter from the FDA dated May 26, 2016 informed the Company that the full clinical hold was replaced and a partial clinical hold was imposed. As a result, patient #1 restarted treatment under IND 43742.

On June 14, 2016, the FDA issued a letter to the Company in connection with the FDA’s inspection of S.R. Burzynski’s manufacturing facility (the “SRB Manufacturing”) in March 2015. The SRB Manufacturing addressed the issues raised in the letter in a response letter submitted to the FDA on July 5, 2016 and in subsequent letters.

On February 20, 2017, BRI informed the FDA of the death of patient #1 on February 19, 2017. No new patients can be enrolled to protocol BT-55 or BT-52 until the partial hold on IND 43742 is lifted. On August 24, 2017, the FDA imposed a full clinical hold on IND 43742 until deficiencies regarding the SRB Manufacturing are resolved.

Table of Contents

Complaint Filed by the Texas Medical Board Against Dr. Burzynski

On March 3, 2017, the Texas Medical Board issued their final ruling regarding the complaint filed on December 11, 2013 and subsequently amended in July 2014 and November 2014, against Dr. Stanislaw R. Burzynski, who serves as our President and the Chairman of our Board of Directors. The Texas Medical Board made allegations that Dr. Burzynski had acted unprofessionally and failed to meet standards of care under the state’s Medical Practice Act. In the final ruling, the Texas Medical Board found that Dr. Burzynski was subject to sanction for various failures that included supervision of foreign medical graduates, untimely and insufficient informed consent, medical record support documentation, tumor measurement reporting inaccuracy, and lack of disclosure of ownership interest in a pharmacy. As a result, Dr. Burzynski was reprimanded. His Texas license was suspended for five years but that suspension was stayed and he was placed under probation under terms and conditions that include having billing practice monitored by a billing monitor for 12 consecutive monitoring cycles, enrolling and completing a physicians education program ethics course, following informed consent protocol, passing the Medical Jurisprudence Examination, and compliance with the Medical Practice Act and other statutes regulating Dr. Burzynski’s practice. As requested as part of the terms and conditions, Dr. Burzynski has completed payment of an administrative penalty and restitution, submission of all informed consent forms for review, submission of an ownership interest disclosure form for review, and he has completed continuing medical education. The Company does not believe that the final order will have an adverse impact on current activities at the Burzynski clinic. However, if any outcomes or changes arise relating to similar matters or future allegations, this could result in substantial harm to the Company’s business and operations.

Termination of License Agreement

Pursuant to the terms of the License Agreement dated June 29, 1983, as superseded by an Amended License Agreement dated April 24, 1989 and a Second Amended License Agreement dated March 1, 1990 between the Company and Dr. Burzynski (collectively, the “License Agreement”), the License Agreement terminated on July 2, 2019 upon the expiration of the last patent licensed to the Company from Dr. Burzynski. As of July 2, 2019, all patents previously licensed by the Company under the License Agreement have expired.

Results of Operations

Three Months Ended May 31, 2022 Compared to Three Months Ended May 31, 2021

Research and development costs were approximately $167,000 and $232,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $65,000 or 28% was due to a decrease in personnel costs of $40,000, consulting and quality control costs of $4,000, facility and equipment costs of $20,000 and materials costs of $1,000, as a result of a reduction of requirements imposed by the Food and Drug Administration.

General and administrative expenses were approximately $64,000 and $84,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $20,000 or 24% was due to an decrease in legal and other professional costs of $21,000, offset by an increase in other costs of $1,000 as a result of a decrease in requests from regulatory agencies.

The Company had net losses of approximately $232,000 and $316,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease in the net loss from 2021 to 2022 is primarily due to an overall decrease in research and development costs and general and administrative expenses of the Company as described above.

Table of Contents

Liquidity and Capital Resources

The Company’s operations have been funded entirely by contributions from Dr. Burzynski and from funds generated from Dr. Burzynski’s medical practice. Effective March 1, 1997, the Company entered into a Research Funding Agreement with Dr. Burzynski (the “Research Funding Agreement”), pursuant to which the Company agreed to undertake all scientific research in connection with the development of new or improved Antineoplastons for the treatment of cancer and Dr. Burzynski agreed to fund the Company’s Antineoplaston research for that purpose. Under the Research Funding Agreement, the Company hires such personnel as is required to conduct Antineoplaston research, and Dr. Burzynski funds the Company’s research expenses, including expenses to conduct the clinical trials. Dr. Burzynski also provides the Company laboratory and research space as needed to conduct the Company’s research activities. The Research Funding Agreement also provides that Dr. Burzynski may fulfill his funding obligations in part by providing the Company such administrative support as is necessary for the Company to manage its business. Dr. Burzynski pays the full amount of the Company’s monthly and annual budget of expenses for the operation of the Company, together with other unanticipated but necessary expenses which the Company incurs.

The amounts which Dr. Burzynski is obligated to pay under the agreement shall be reduced dollar for dollar by the following: (1) any income which the Company receives for services provided to other companies for research and/or development of other products, less such identifiable marginal or additional expenses necessary to produce such income, or (2) the net proceeds of any stock offering or private placement which the Company receives during the term of the agreement up to a maximum of $1,000,000 in a given Company fiscal year.

The Research Funding Agreement, as amended, contains an annual automatic renewal provision providing for an additional one-year term, unless one party notifies the other party at least thirty days prior to the expiration of the then current term of the agreement of its intention not to renew the agreement. Subject to the foregoing, the term of the Research Funding Agreement was renewed and extended until February 28, 2023. It is expected that the Research Funding Agreement will continue to renew each year prospectively unless terminated under the provisions of the agreement.

The Research Funding Agreement automatically terminates in the event that Dr. Burzynski owns less than fifty percent of the outstanding shares of the Company, or is removed as President and/or Chairman of the Board of the Company, unless Dr. Burzynski notifies the Company in writing of his intention to continue the agreement notwithstanding this automatic termination provision.

The Company estimates that it will spend approximately $750,000 during the remaining three quarters of the fiscal year ending February 28, 2023. While the Company anticipates that Dr. Burzynski will continue to fund the Company’s research and FDA- related costs, there is no assurance that Dr. Burzynski will be able to continue to fund the Company’s operations pursuant to the Research Funding Agreement or otherwise. In addition, Dr. Burzynski’s medical practice has successfully funded the Company’s research activities over the last 25 years and, in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene-targeted therapy, immunotherapy and hormonal therapy.

Because the Company currently is entirely dependent upon the contributions for research provided by Dr. Burzynski under the Research Funding Agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under the Research Funding Agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.

Table of Contents

Item 4. Controls and Procedures

Within the 90 days prior to the date of this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive and financial officers, of the effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-14 under the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Company’s principal executive and financial officers concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information required to be included in periodic filings with the Securities and Exchange Commission. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. There were no significant changes in the Company’s internal controls or in other factors that could significantly affect internal controls over financial reporting that occurred during the fiscal quarter ended May 31, 2022 that have materially affected or are reasonably likely to materially affect our internal controls subsequent to that date.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

The Company’s activities are subject to regulation by various governmental agencies, including the FDA, which regularly monitor the Company’s operations and often impose requirements on the conduct of its clinical trials and other aspects of the Company’s business operations. The Company’s policy is to comply with all such regulatory requirements. From time to time, the Company is also subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The Company seeks to minimize its exposure to claims of this type wherever possible.

Currently, the Company is not a party to any material pending legal proceedings. Moreover, the Company is not aware of any such legal proceedings that are contemplated by governmental authorities with respect to the Company or any of its properties.

Table of Contents

Item 6. Exhibits


3.1		Certificate of Incorporation of the Company, as amended (incorporated by reference from Exhibits 3(i)— (iii) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No.000-23425)).

3.2		Amended Bylaws of the Company (incorporated by reference from Exhibit 3 (iv) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No.000-23425)).

31.1		Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as amended, filed herewith.

31.2		Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as amended, filed herewith.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	BURZYNSKI RESEARCH INSTITUTE, INC.

	By:	/s/ Stanislaw R. Burzynski
		Stanislaw R. Burzynski,
		President and Chairman of the Board of Directors
		(Principal Executive Officer)

Date: July 14, 2022

EX-31.1 2 bzyr-20220531xex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Stanislaw R. Burzynski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Burzynski Research Institute, Inc. (“BRI”);

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of BRI as of, and for, the periods presented in this quarterly report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for BRI and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to BRI is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designated such internal control over financial reporting, or caused such internal control over financial reporting to be designated under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of BRI’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

(d)

Disclosed in this quarterly report any change in BRI’s internal control over financial reporting that occurred during BRI’s most recent fiscal quarter (BRI’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, BRI’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to BRI’s auditors and the audit committee of BRI’s board of directors (or persons performing the equivalent functions of an audit committee):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect BRI’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in BRI’s internal control over financial reporting.


Date: July 14, 2022	/s/ Stanislaw R. Burzynski
	Stanislaw R. Burzynski,
	President and Chairman of the Board of Directors
	(Principal Executive Officer)

EX-31.2 3 bzyr-20220531xex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Patryk P. Goscianski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Burzynski Research Institute, Inc. (“BRI”);

(a)

(b)

(c)

(d)

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect BRI’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in BRI’s internal control over financial reporting.


Date: July 14, 2022	/s/ Patryk P. Goscianski
	Patryk P. Goscianski,
	Secretary and Treasurer
	(Principal Financial Officer)

EX-32.1 4 bzyr-20220531xex32d1.htm EX-32.1

EXHIBIT 32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. § 1350

(Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Quarterly Report of Burzynski Research Institute, Inc. (the “Company”) on Form 10-Q for the period ended May 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Burzynski Research Institute, Inc. and will be retained by Burzynski Research Institute, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


Date: July 14, 2022
	/s/ Stanislaw R. Burzynski
	Stanislaw R. Burzynski
	President and Chairman of the Board of Directors
	(Principal Executive Officer)

EX-32.2 5 bzyr-20220531xex32d2.htm EX-32.2

EXHIBIT 32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. § 1350

(Section 906 of the Sarbanes-Oxley Act of 2002)

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: July 14, 2022

	/s/ Patryk P. Goscianski
	Patryk P. Goscianski
	Secretary and Treasurer
	(Principal Financial Officer)

EX-101.SCH 6 bzyr-20220531.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - ECONOMIC DEPENDENCY link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bzyr-20220531_cal.xml EX-101.CAL EX-101.DEF 8 bzyr-20220531_def.xml EX-101.DEF EX-101.LAB 9 bzyr-20220531_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Statement Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Amendment Flag Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense, Current Prepaids Assets, Current Total current assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Liabilities CURRENT AND TOTAL LIABILITIES Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity (deficit) Common Stock, Value, Issued Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of May 31, 2022 and February 28, 2022 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity (deficit) Liabilities and Equity Total liabilities and stockholders' equity (deficit) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding STATEMENTS OF OPERATIONS Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income tax Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss LOSS PER COMMON SHARE Earnings per share information: Earnings Per Share, Basic Loss per common share Basic Earnings Per Share, Diluted Loss per common share Diluted Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding Basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding Diluted STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-in Capital Retained Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Represents the cash contributed by the individual that is reported as additional paid-in capital, which is used to fund general operating expenses during the reporting year. Adjustments to Additional Paid in Capital, Cash Contributed Cash contributed by S.R. Burzynski, M.D., Ph.D. Adjustments to Additional Paid in Capital, Clinical Trial Expenses FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used by operating activities: Represents the clinical trial expenses that are incurred by the entity which are used in the treatment of cancer during the reporting period. Clinical Trial Expenses Paid FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities Increase (Decrease) in Prepaid Expense Prepaids Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued liabilities Net Cash Provided by (Used in) Operating Activities NET CASH USED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Contributed Capital Contribution of capital Net Cash Provided by (Used in) Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect NET INCREASE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AT END OF PERIOD CASH AT BEGINNING OF PERIOD BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] BASIS OF PRESENTATION ECONOMIC DEPENDENCY Stockholders' Equity Note Disclosure [Text Block] ECONOMIC DEPENDENCY STOCK OPTIONS AND WARRANTS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK OPTIONS AND WARRANTS Earnings Per Share [Text Block] LOSS PER COMMON SHARE INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES Schedule of Share Based Compensation Arrangement by Share Based Payment Award Options Vested [Table Text Block] Schedule of options vested Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board. Ownership Interest Percentage Held by Company President and Chairman of Board Percentage of outstanding stock owned by the President and Chairman of the Board Represents the number of antineoplaston drugs that have received FDA approval. Number of Antineoplaston Drugs that Received FDA Approval Number of antineoplaston drugs that have received FDA approval Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Domain] Stock options Legal Entity [Axis] Entity [Domain] Represents information pertaining to Worldwide Medical Consultants Inc. Worldwide Medical Consultants, Inc. ("WMC") Related Party [Axis] Related Party [Domain] Represents information pertaining to Carigen Ltd., an entity wholly owned and controlled by Dr. Burzynski. CARIGEN, LTD ("SRB") Share-based Compensation Arrangement by Share-based Payment Award [Line Items] STOCK OPTIONS AND WARRANTS The number of share-based compensation plans approved by the entity's shareholders. Share Based Compensation Arrangement, by Share Based Payment Award, Number of Plans Number of stock-based employee compensation plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Marketing Agreement [Abstract] Marketing Agreement Represents the percentage of consulting fee to be received by the Company per the marketing agreement. Percentage of Consulting Fee to be Received as Per Agreement Consulting fee (as a percent) Class of Warrant or Right Number of Securities to be Called by Warrants or Rights WMC Payment Consideration Warrants to be granted to acquire shares of common stock (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights Exercisable price (in dollars per share) Represents the exercise period for warrants exercisable. Class of Warrant or Rights Exercise Period Warrants exercise period Represents the shares vesting upon execution of the agreement. Shares Vesting upon Execution of Agreement Shares vesting upon execution of the agreement Represents the remaining shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the marketing agreement. Remaining Shares to Vest upon First Closing of Agreement Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement Warrants or Rights Fair Value Fair value of vested warrants at date of grant Represents the fair value of warrants or rights per share at the date of grant. Warrant or Right Fair Value Per Warrant Fair value of vested warrants at date of grant (in dollars per share) Represents the number of warrants exercised as of the date. Class of Warrant or Rights Warrants Exercised Number Warrants exercised (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Warrants and stock options excluded from calculation of diluted loss per share (in shares) Income Tax Examination [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] IRS Income Tax Examination [Line Items] Income Taxes Represents the period after filing income tax returns subject to examination by the taxing authority. Income Tax Examination, Period after Filing Income Tax Returns Subject to Examination Period after filing income tax returns subject to examination Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate U.S. federal income tax rate (as a percent) Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract] Actual income tax benefit Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate Expected expense (benefit) Income Tax Reconciliation, Deductions Taxes directly to Dr. Burzynski Income Tax Reconciliation, Nondeductible Expense Nondeductible expenses and other adjustments Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance Change in valuation allowance Income Tax Expense (Benefit) Provision for income tax Deferred Tax Assets, Net [Abstract] Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance Net deferred tax asset Deferred Tax Assets, Valuation Allowance Valuation allowance Revenues Historical earnings Operating Loss Carryforwards [Table] Tax Period [Axis] Tax Period [Domain] 2026 to 2038 Scenario [Axis] Scenario, Unspecified [Domain] Represents information relating to 100% future taxable income. 100% of future taxable income Represents information relating to 80% future taxable income. 80% of future taxable income Operating Loss Carryforwards [Line Items] Net operating loss carryforwards The percentage of future taxable income for which net operating loss carryforward indefinitely. Percentage of Future Taxable Income, Net Operating Loss Carryforwards Future taxable income (in Percent) Represents the percentage of NOL limit on taxable income under the CARES act. Percentage on Net Operating loss Carryforwards Limit of Taxable Income Under Coronavirus Aid, Relief, and Economic Security Act Percentage of NOL limit on taxable income under the CARES act The amount of net operating loss carryforwards that will carryforward in accordance with Tax Cuts and Jobs Act of 2017. Tax Cuts and Jobs Act of 2017, Net Operating Loss Carryforwards Net operating loss carryforward in accordance with the Act It represents net operating loss carryforward indefinite period. Net Operating Loss Carry Forward Indefinitely Net operating loss carryforward indefinite period EX-101.PRE 10 bzyr-20220531_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	May 31, 2022	Jun. 30, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	May 31, 2022
Entity File Number	000-23425
Entity Registrant Name	BURZYNSKI RESEARCH INSTITUTE INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	76-0136810
Entity Address, Address Line One	9432 Katy Freeway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77055
City Area Code	713
Local Phone Number	335-5697
Title of 12(b) Security	None
Trading Symbol	BZYR
Amendment Flag	false
Security Exchange Name	NONE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		131,448,444
Entity Central Index Key	0000724445
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1

XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	May 31, 2022	Feb. 28, 2022
Current assets
Cash and cash equivalents	$ 4,766	$ 3,382
Prepaids	700	1,279
Total current assets	5,466	4,661
Total assets	5,466	4,661
Current liabilities
Accounts payable	13,925
Accrued liabilities	30,221	3,455
CURRENT AND TOTAL LIABILITIES	44,146	3,455
Commitments and contingencies
Stockholders' equity (deficit)
Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of May 31, 2022 and February 28, 2022	131,449	131,449
Additional paid-in capital	125,900,091	125,708,240
Retained deficit	(126,070,220)	(125,838,483)
Total stockholders' equity (deficit)	(38,680)	1,206
Total liabilities and stockholders' equity (deficit)	$ 5,466	$ 4,661

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	May 31, 2022	Feb. 28, 2022
BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	131,448,444	131,448,444
Common stock, shares outstanding	131,448,444	131,448,444

XML 14 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	May 31, 2022	May 31, 2021
Operating expenses
Research and development	$ 167,354	$ 231,946
General and administrative	64,383	84,337
Total operating expenses	231,737	316,283
Operating loss	(231,737)	(316,283)
Loss before provision for income tax	(231,737)	(316,283)
Net loss	$ (231,737)	$ (316,283)
Earnings per share information:
Loss per common share Basic	$ 0.00	$ 0.00
Loss per common share Diluted	$ 0.00	$ 0.00
Weighted average number of common shares outstanding Basic	131,448,444	131,448,444
Weighted average number of common shares outstanding Diluted	131,448,444	131,448,444

XML 15 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2021	$ 131,449	$ 124,684,535	$ (124,861,827)	$ (45,843)
Balance (in shares) at Feb. 28, 2021	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		84,967		84,967
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		215,926		215,926
Net loss			(316,283)	(316,283)
Balance at May. 31, 2021	$ 131,449	124,985,428	(125,178,110)	(61,233)
Balance (in shares) at May. 31, 2021	131,448,444
Balance at Feb. 28, 2022	$ 131,449	125,708,240	(125,838,483)	1,206
Balance (in shares) at Feb. 28, 2022	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.		40,517		40,517
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D		151,334		151,334
Net loss			(231,737)	(231,737)
Balance at May. 31, 2022	$ 131,449	$ 125,900,091	$ (126,070,220)	$ (38,680)
Balance (in shares) at May. 31, 2022	131,448,444

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	May 31, 2022	May 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (231,737)	$ (316,283)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	151,334	215,926
Changes in operating assets and liabilities
Prepaids	579	(521)
Accounts payable	13,925	(2,071)
Accrued liabilities	26,766	18,514
NET CASH USED BY OPERATING ACTIVITIES	(39,133)	(84,435)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	40,517	84,967
NET CASH PROVIDED BY FINANCING ACTIVITIES	40,517	84,967
NET INCREASE IN CASH	1,384	532
CASH AT BEGINNING OF PERIOD	3,382	62
CASH AT END OF PERIOD	$ 4,766	$ 594

XML 17 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

3 Months Ended

May 31, 2022

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE A.

BASIS OF PRESENTATION

XML 18 R8.htm IDEA: XBRL DOCUMENT

ECONOMIC DEPENDENCY

3 Months Ended

May 31, 2022

ECONOMIC DEPENDENCY

ECONOMIC DEPENDENCY

NOTE B.

ECONOMIC DEPENDENCY

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

3 Months Ended

May 31, 2022

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS

NOTE C.

STOCK OPTIONS AND WARRANTS

At May 31, 2022, the Company had one stock-based employee compensation plan, which is described below.

On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35 per share, to an officer who is no longer with the Company. The options vested as follows:


		Vesting Date
400,000	options	September 14, 1996
100,000	options	June 1, 1997
100,000	options	June 1, 1998

The options are valid in perpetuity. None of the options have been exercised as of May 31, 2022.

XML 20 R10.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE

3 Months Ended

May 31, 2022

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE

NOTE D.

LOSS PER COMMON SHARE

XML 21 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

May 31, 2022

INCOME TAXES

INCOME TAXES

NOTE E.

INCOME TAXES

The Company follows the provisions of FASB ASC 740, Income Taxes. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.

The Company recognizes interest and penalties as interest expense when they are accrued or assessed.

The federal income tax returns of the Company for 2020, 2019, and 2018 are subject to examination by the IRS, generally for three years after they are filed.


	Three Months Ended May 31,
	2022		2021
Expected expense (benefit)	$	(48,665)	$	(66,419)
Taxed directly to Dr. Burzynski		48,665		66,419
Nondeductible expenses and other adjustments		8,376		3,232
Change in valuation allowance		(8,376)		(3,232)
State taxes		—		—
Provision for income tax	$	—	$	—

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

3 Months Ended

May 31, 2022

STOCK OPTIONS AND WARRANTS

Schedule of options vested


		Vesting Date
400,000	options	September 14, 1996
100,000	options	June 1, 1997
100,000	options	June 1, 1998

XML 23 R13.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

3 Months Ended

May 31, 2022

INCOME TAXES

Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss


	Three Months Ended May 31,
	2022		2021
Expected expense (benefit)	$	(48,665)	$	(66,419)
Taxed directly to Dr. Burzynski		48,665		66,419
Nondeductible expenses and other adjustments		8,376		3,232
Change in valuation allowance		(8,376)		(3,232)
State taxes		—		—
Provision for income tax	$	—	$	—

XML 24 R14.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details)	3 Months Ended
BASIS OF PRESENTATION (Details)	May 31, 2022 item
BASIS OF PRESENTATION
Percentage of outstanding stock owned by the President and Chairman of the Board	81.00%
Number of antineoplaston drugs that have received FDA approval	0

XML 25 R15.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Details)					3 Months Ended
STOCK OPTIONS AND WARRANTS (Details)	Jul. 05, 2012 USD ($) $ / shares $ / item shares	Jun. 01, 1998 shares	Jun. 01, 1997 shares	Sep. 14, 1996 $ / shares shares	May 31, 2022 item shares
STOCK OPTIONS AND WARRANTS
Number of stock-based employee compensation plan \| item					1
Worldwide Medical Consultants, Inc. ("WMC") \| CARIGEN, LTD ("SRB")
Marketing Agreement
Consulting fee (as a percent)	10.00%
Warrants to be granted to acquire shares of common stock (in shares)	2,000,000
Exercisable price (in dollars per share) \| $ / shares	$ 0.10
Warrants exercise period	10 years
Shares vesting upon execution of the agreement	1,000,000
Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement	1,000,000
Fair value of vested warrants at date of grant \| $	$ 160,000
Fair value of vested warrants at date of grant (in dollars per share) \| $ / item	0.16
Warrants exercised (in shares)					0
Stock options
STOCK OPTIONS AND WARRANTS
Granted (in shares)				600,000
Exercise price (in dollars per share) \| $ / shares				$ 0.35
Vested (in shares)		100,000	100,000	400,000
Exercised (in shares)					0

XML 26 R16.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE (Details) - shares	3 Months Ended
LOSS PER COMMON SHARE (Details) - shares	May 31, 2022	May 31, 2021
LOSS PER COMMON SHARE
Warrants and stock options excluded from calculation of diluted loss per share (in shares)	1,600,000	1,600,000

XML 27 R17.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($)	3 Months Ended
INCOME TAXES (Details) - USD ($)	May 31, 2022	May 31, 2021
Income Taxes
U.S. federal income tax rate (as a percent)	21.00%	21.00%
Actual income tax benefit
Expected expense (benefit)	$ (48,665)	$ (66,419)
Taxes directly to Dr. Burzynski	48,665	66,419
Nondeductible expenses and other adjustments	8,376	3,232
Change in valuation allowance	(8,376)	$ (3,232)
Deferred tax assets:
Net deferred tax asset	0
Valuation allowance	167,078
Historical earnings	$ 0
IRS
Income Taxes
Period after filing income tax returns subject to examination	3 years

XML 28 R18.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Operating Loss Carryforwards (Details)	3 Months Ended
INCOME TAXES - Operating Loss Carryforwards (Details)	May 31, 2022 USD ($)
Net operating loss carryforwards
Future taxable income (in Percent)	80.00%
Percentage of NOL limit on taxable income under the CARES act	80.00%
Net operating loss carryforward indefinite period	$ 118,834
100% of future taxable income
Net operating loss carryforwards
Future taxable income (in Percent)	100.00%
Net operating loss carryforward indefinite period	$ 78,948
80% of future taxable income
Net operating loss carryforwards
Future taxable income (in Percent)	80.00%
Net operating loss carryforward indefinite period	$ 39,886
2026 to 2038
Net operating loss carryforwards
Net operating loss carryforward in accordance with the Act	$ 473,902

XML 29 bzyr-20220531x10q_htm.xml IDEA: XBRL DOCUMENT 0000724445 us-gaap:EmployeeStockOptionMember 2022-03-01 2022-05-31 0000724445 us-gaap:RetainedEarningsMember 2022-05-31 0000724445 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0000724445 us-gaap:RetainedEarningsMember 2022-02-28 0000724445 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0000724445 us-gaap:RetainedEarningsMember 2021-05-31 0000724445 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0000724445 us-gaap:RetainedEarningsMember 2021-02-28 0000724445 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0000724445 us-gaap:CommonStockMember 2022-05-31 0000724445 us-gaap:CommonStockMember 2022-02-28 0000724445 us-gaap:CommonStockMember 2021-05-31 0000724445 us-gaap:CommonStockMember 2021-02-28 0000724445 us-gaap:EmployeeStockOptionMember 1998-06-01 1998-06-01 0000724445 us-gaap:EmployeeStockOptionMember 1997-06-01 1997-06-01 0000724445 us-gaap:EmployeeStockOptionMember 1996-09-14 1996-09-14 0000724445 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0000724445 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0000724445 2021-05-31 0000724445 2021-02-28 0000724445 2022-02-28 0000724445 2022-06-30 0000724445 bzyr:CarigenLtdMember bzyr:WorldwideMedicalConsultantsIncMember 2012-07-05 0000724445 us-gaap:LatestTaxYearMember 2022-05-31 0000724445 2022-05-31 0000724445 bzyr:HundredPercentFutureTaxableIncomeMember 2022-03-01 2022-05-31 0000724445 bzyr:EightyPercentFutureTaxableIncomeMember 2022-03-01 2022-05-31 0000724445 us-gaap:InternalRevenueServiceIRSMember 2022-03-01 2022-05-31 0000724445 bzyr:CarigenLtdMember bzyr:WorldwideMedicalConsultantsIncMember 2022-05-31 0000724445 bzyr:CarigenLtdMember bzyr:WorldwideMedicalConsultantsIncMember 2012-07-05 2012-07-05 0000724445 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0000724445 2022-03-01 2022-05-31 0000724445 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0000724445 2021-03-01 2021-05-31 iso4217:USD shares bzyr:item pure iso4217:USD bzyr:item iso4217:USD shares

BURZYNSKI RESEARCH INSTITUTE INC 0000724445 --02-28 2023 Q1 false

0.00

131448444

NONE

131448444

10-Q true 2022-05-31 false 000-23425 DE 76-0136810 9432 Katy Freeway Suite 200 Houston TX 77055 713 335-5697 None BZYR Yes Yes Non-accelerated Filer true false false 131448444

4766

3382

700

1279

5466

4661

5466

4661

13925

30221

3455

44146

3455

0.001

200000000

131448444

131449

125900091

125708240

-126070220

-125838483

-38680

1206

5466

4661

167354

231946

64383

84337

231737

316283

-231737

-316283

-231737

-316283

-231737

-316283

0.00

131448444

131449

125708240

-125838483

1206

40517 40517

151334

-231737

131448444

131449

125900091

-126070220

-38680

131448444

131449

124684535

-124861827

-45843

84967 84967

215926

-316283

131448444

131449

124985428

-125178110

-61233

-231737

-316283

151334 215926

-579

521

13925

-2071

26766

18514

-39133

-84435

40517

84967

40517

84967

1384

532

3382

4766

594

0.810 0

600000

0.35

400000

100000

0.10

2000000

0.10

P10Y 1000000 1000000

160000

0.16 0

1600000

<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;">NOTE E.</td><td style="padding:0pt;">INCOME TAXES</td></tr></table>The Company follows the provisions of FASB ASC 740, Income Taxes. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.The Company recognizes interest and penalties as interest expense when they are accrued or assessed.The federal income tax returns of the Company for 2020, 2019, and 2018 are subject to examination by the IRS, generally for three years after they are filed.The actual provision for income tax for the three months ended May 31, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:<div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended May 31,</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">Expected expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"> (48,665)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> (66,419)</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Taxed directly to Dr. Burzynski </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"> 48,665</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> 66,419</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">Nondeductible expenses and other adjustments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"> 8,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 3,232</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"> (8,376)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> (3,232)</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">State taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Provision for income tax</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table></div>At May 31, 2022, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $167,078. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has no historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of 80% of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to 80% of future taxable income according to the Act.As of May 31, 2022, the Company has net operating loss carryforwards in the amount of $473,902 that will expire between 2026 and 2038, and $118,834 that will carryforward indefinitely, of which $78,948 applies to 100% of future taxable income and $39,886 applies to 80% of future taxable income.

P3Y

0.21

<div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended May 31,</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">Expected expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"> (48,665)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> (66,419)</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Taxed directly to Dr. Burzynski </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"> 48,665</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> 66,419</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">Nondeductible expenses and other adjustments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"> 8,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 3,232</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"> (8,376)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> (3,232)</td></tr><tr><td style="vertical-align:bottom;width:73.99%;background:#cceeff;margin:0pt;padding:0pt;">State taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:73.99%;margin:0pt;padding:0pt;">Provision for income tax</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table></div>

-48665

-66419

48665

66419

8376

3232

-8376

-3232

167078

0.80 0.80 0.80 473902 118834 78948 1 39886 0.80

EXCEL 30 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 34 106 1 false 10 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - BALANCE SHEETS Sheet http://www.burzynskiresearch.com/role/StatementBalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - STATEMENTS OF OPERATIONS Sheet http://www.burzynskiresearch.com/role/StatementStatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00400 - Statement - STATEMENTS OF CASH FLOWS Sheet http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - BASIS OF PRESENTATION Sheet http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 10201 - Disclosure - ECONOMIC DEPENDENCY Sheet http://www.burzynskiresearch.com/role/DisclosureEconomicDependency ECONOMIC DEPENDENCY Notes 8 false false R9.htm 10301 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants STOCK OPTIONS AND WARRANTS Notes 9 false false R10.htm 10401 - Disclosure - LOSS PER COMMON SHARE Sheet http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare LOSS PER COMMON SHARE Notes 10 false false R11.htm 10501 - Disclosure - INCOME TAXES Sheet http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 11 false false R12.htm 30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants 12 false false R13.htm 30503 - Disclosure - INCOME TAXES (Tables) Sheet http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables INCOME TAXES (Tables) Tables http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes 13 false false R14.htm 40101 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails BASIS OF PRESENTATION (Details) Details http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation 14 false false R15.htm 40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) Sheet http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails STOCK OPTIONS AND WARRANTS (Details) Details http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables 15 false false R16.htm 40401 - Disclosure - LOSS PER COMMON SHARE (Details) Sheet http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails LOSS PER COMMON SHARE (Details) Details http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare 16 false false R17.htm 40501 - Disclosure - INCOME TAXES (Details) Sheet http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails INCOME TAXES (Details) Details http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables 17 false false R18.htm 40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details) Sheet http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails INCOME TAXES - Operating Loss Carryforwards (Details) Details 18 false false All Reports Book All Reports bzyr-20220531x10q.htm bzyr-20220531.xsd bzyr-20220531_cal.xml bzyr-20220531_def.xml bzyr-20220531_lab.xml bzyr-20220531_pre.xml bzyr-20220531xex31d1.htm bzyr-20220531xex31d2.htm bzyr-20220531xex32d1.htm bzyr-20220531xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 36 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bzyr-20220531x10q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 34, "dts": { "calculationLink": { "local": [ "bzyr-20220531_cal.xml" ] }, "definitionLink": { "local": [ "bzyr-20220531_def.xml" ] }, "inline": { "local": [ "bzyr-20220531x10q.htm" ] }, "labelLink": { "local": [ "bzyr-20220531_lab.xml" ] }, "presentationLink": { "local": [ "bzyr-20220531_pre.xml" ] }, "schema": { "local": [ "bzyr-20220531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 163, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 8, "http://xbrl.sec.gov/dei/2022": 7, "total": 15 }, "keyCustom": 16, "keyStandard": 90, "memberCustom": 4, "memberStandard": 6, "nsprefix": "bzyr", "nsuri": "http://www.burzynskiresearch.com/20220531", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - LOSS PER COMMON SHARE", "role": "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare", "shortName": "LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - INCOME TAXES", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables", "shortName": "STOCK OPTIONS AND WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "3", "first": true, "lang": null, "name": "bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - BASIS OF PRESENTATION (Details)", "role": "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails", "shortName": "BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "3", "first": true, "lang": null, "name": "bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "INF", "first": true, "lang": null, "name": "bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_sqywRvE1-UKcREfsEGH_Wg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails", "shortName": "STOCK OPTIONS AND WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "INF", "first": true, "lang": null, "name": "bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_sqywRvE1-UKcREfsEGH_Wg", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - LOSS PER COMMON SHARE (Details)", "role": "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails", "shortName": "LOSS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_xBAB3NakK0-E34Ta-4UyPQ", "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - INCOME TAXES (Details)", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "2", "first": true, "lang": null, "name": "bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails", "shortName": "INCOME TAXES - Operating Loss Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "2", "first": true, "lang": null, "name": "bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_kYQvjyebIkiS4aufN0sUhw", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - BALANCE SHEETS", "role": "http://www.burzynskiresearch.com/role/StatementBalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_5_31_2022_o67K1utCIEqYfT-MciHBUg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_9ex5mUlT9k-j1X5FUzHr0Q", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - STATEMENTS OF OPERATIONS", "role": "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RordQiOIW0mmuvypCou0nw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RordQiOIW0mmuvypCou0nw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS", "role": "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": "0", "lang": null, "name": "bzyr:ClinicalTrialExpensesPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD__JiH8xtarEKpy_j5iK_OmA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - BASIS OF PRESENTATION", "role": "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - ECONOMIC DEPENDENCY", "role": "http://www.burzynskiresearch.com/role/DisclosureEconomicDependency", "shortName": "ECONOMIC DEPENDENCY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - STOCK OPTIONS AND WARRANTS", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants", "shortName": "STOCK OPTIONS AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20220531x10q.htm", "contextRef": "Duration_3_1_2022_To_5_31_2022__LHrnga5AEqzSAead-Y7aw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 10, "tag": { "bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the cash contributed by the individual that is reported as additional paid-in capital, which is used to fund general operating expenses during the reporting year.", "label": "Adjustments to Additional Paid in Capital, Cash Contributed", "terseLabel": "Cash contributed by S.R. Burzynski, M.D., Ph.D." } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalCashContributed", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bzyr_CarigenLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Carigen Ltd., an entity wholly owned and controlled by Dr. Burzynski.", "label": "CARIGEN, LTD (\"SRB\")" } } }, "localname": "CarigenLtdMember", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "bzyr_ClassOfWarrantOrRightsExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the exercise period for warrants exercisable.", "label": "Class of Warrant or Rights Exercise Period", "terseLabel": "Warrants exercise period" } } }, "localname": "ClassOfWarrantOrRightsExercisePeriod", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "bzyr_ClassOfWarrantOrRightsWarrantsExercisedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants exercised as of the date.", "label": "Class of Warrant or Rights Warrants Exercised Number", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightsWarrantsExercisedNumber", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "bzyr_ClinicalTrialExpensesPaid": { "auth_ref": [], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the clinical trial expenses that are incurred by the entity which are used in the treatment of cancer during the reporting period.", "label": "Clinical Trial Expenses Paid", "terseLabel": "FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D." } } }, "localname": "ClinicalTrialExpensesPaid", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bzyr_EightyPercentFutureTaxableIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 80% future taxable income.", "label": "80% of future taxable income" } } }, "localname": "EightyPercentFutureTaxableIncomeMember", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "bzyr_HundredPercentFutureTaxableIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 100% future taxable income.", "label": "100% of future taxable income" } } }, "localname": "HundredPercentFutureTaxableIncomeMember", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period after filing income tax returns subject to examination by the taxing authority.", "label": "Income Tax Examination, Period after Filing Income Tax Returns Subject to Examination", "terseLabel": "Period after filing income tax returns subject to examination" } } }, "localname": "IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "durationItemType" }, "bzyr_MarketingAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketing Agreement [Abstract]", "terseLabel": "Marketing Agreement" } } }, "localname": "MarketingAgreementAbstract", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "bzyr_NetOperatingLossCarryForwardIndefinitely": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents net operating loss carryforward indefinite period.", "label": "Net Operating Loss Carry Forward Indefinitely", "terseLabel": "Net operating loss carryforward indefinite period" } } }, "localname": "NetOperatingLossCarryForwardIndefinitely", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of antineoplaston drugs that have received FDA approval.", "label": "Number of Antineoplaston Drugs that Received FDA Approval", "terseLabel": "Number of antineoplaston drugs that have received FDA approval" } } }, "localname": "NumberOfAntineoplastonDrugsThatReceivedFDAApproval", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board.", "label": "Ownership Interest Percentage Held by Company President and Chairman of Board", "terseLabel": "Percentage of outstanding stock owned by the President and Chairman of the Board" } } }, "localname": "OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of consulting fee to be received by the Company per the marketing agreement.", "label": "Percentage of Consulting Fee to be Received as Per Agreement", "terseLabel": "Consulting fee (as a percent)" } } }, "localname": "PercentageOfConsultingFeeToBeReceivedAsPerAgreement", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of future taxable income for which net operating loss carryforward indefinitely.", "label": "Percentage of Future Taxable Income, Net Operating Loss Carryforwards", "terseLabel": "Future taxable income (in Percent)" } } }, "localname": "PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of NOL limit on taxable income under the CARES act.", "label": "Percentage on Net Operating loss Carryforwards Limit of Taxable Income Under Coronavirus Aid, Relief, and Economic Security Act", "terseLabel": "Percentage of NOL limit on taxable income under the CARES act" } } }, "localname": "PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "percentItemType" }, "bzyr_RemainingSharesToVestUponFirstClosingOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the remaining shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the marketing agreement.", "label": "Remaining Shares to Vest upon First Closing of Agreement", "terseLabel": "Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement" } } }, "localname": "RemainingSharesToVestUponFirstClosingOfAgreement", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share-based compensation plans approved by the entity's shareholders.", "label": "Share Based Compensation Arrangement, by Share Based Payment Award, Number of Plans", "terseLabel": "Number of stock-based employee compensation plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "integerItemType" }, "bzyr_SharesVestingUponExecutionOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares vesting upon execution of the agreement.", "label": "Shares Vesting upon Execution of Agreement", "terseLabel": "Shares vesting upon execution of the agreement" } } }, "localname": "SharesVestingUponExecutionOfAgreement", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of net operating loss carryforwards that will carryforward in accordance with Tax Cuts and Jobs Act of 2017.", "label": "Tax Cuts and Jobs Act of 2017, Net Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward in accordance with the Act" } } }, "localname": "TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "bzyr_WarrantOrRightFairValuePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the fair value of warrants or rights per share at the date of grant.", "label": "Warrant or Right Fair Value Per Warrant", "terseLabel": "Fair value of vested warrants at date of grant (in dollars per share)" } } }, "localname": "WarrantOrRightFairValuePerWarrant", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "perUnitItemType" }, "bzyr_WorldwideMedicalConsultantsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Worldwide Medical Consultants Inc.", "label": "Worldwide Medical Consultants, Inc. (\"WMC\")" } } }, "localname": "WorldwideMedicalConsultantsIncMember", "nsuri": "http://www.burzynskiresearch.com/20220531", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r46", "r51", "r89", "r118" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r46", "r51", "r89", "r118", "r201" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r200" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r9" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r39", "r40", "r41", "r151", "r152", "r153", "r183" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Clinical Trial Expenses", "verboseLabel": "FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Warrants and stock options excluded from calculation of diluted loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r6", "r36", "r70", "r73", "r79", "r85", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r177", "r179", "r186", "r198", "r200", "r217", "r223" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r15", "r36", "r85", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r177", "r179", "r186", "r198", "r200" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r5", "r33" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r29", "r33", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AT END OF PERIOD", "periodStartLabel": "CASH AT BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r29", "r187" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercisable price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right Number of Securities to be Called by Warrants or Rights WMC Payment Consideration", "terseLabel": "Warrants to be granted to acquire shares of common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r219", "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r39", "r40", "r183" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r200" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of May 31, 2022 and February 28, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r121", "r122", "r148", "r149", "r150", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE", "terseLabel": "Earnings per share information:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r26", "r43", "r44", "r45", "r46", "r47", "r52", "r55", "r57", "r58", "r59", "r63", "r64", "r184", "r185", "r221", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per common share Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r26", "r43", "r44", "r45", "r46", "r47", "r55", "r57", "r58", "r59", "r63", "r64", "r184", "r185", "r221", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per common share Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r60", "r61", "r62", "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r37", "r157", "r171" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate", "terseLabel": "U.S. federal income tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r21", "r22", "r23", "r39", "r40", "r41", "r42", "r48", "r50", "r66", "r86", "r113", "r115", "r151", "r152", "r153", "r167", "r168", "r183", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r70", "r72", "r75", "r78", "r80", "r216", "r220", "r222", "r228" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Loss before provision for income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r37", "r158", "r161", "r164", "r169", "r172", "r174", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r38", "r49", "r50", "r69", "r156", "r170", "r173", "r229" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]", "terseLabel": "Actual income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r157" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDeductions": { "auth_ref": [ "r157" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Income Tax Reconciliation, Deductions", "terseLabel": "Taxes directly to Dr. Burzynski" } } }, "localname": "IncomeTaxReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r157" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate", "verboseLabel": "Expected expense (benefit)" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r157" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Income Tax Reconciliation, Nondeductible Expense", "terseLabel": "Nondeductible expenses and other adjustments" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r31" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r31" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r31" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaids" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "IRS" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Latest identified tax year.", "label": "2026 to 2038" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r36", "r74", "r85", "r90", "r91", "r92", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r178", "r179", "r180", "r186", "r198", "r199" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "CURRENT AND TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r36", "r85", "r186", "r200", "r218", "r225" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r29" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r29", "r30", "r32" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r43", "r44", "r45", "r46", "r52", "r53", "r56", "r59", "r70", "r72", "r75", "r78", "r80" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows", "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations", "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r70", "r72", "r75", "r78", "r80" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r14", "r87", "r88" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaids" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromContributedCapital": { "auth_ref": [ "r28" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.", "label": "Proceeds from Contributed Capital", "verboseLabel": "Contribution of capital" } } }, "localname": "ProceedsFromContributedCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r117", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r117", "r195", "r197", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r155", "r202", "r235" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r115", "r200", "r224", "r233", "r234" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r39", "r40", "r41", "r42", "r48", "r50", "r86", "r151", "r152", "r153", "r167", "r168", "r183", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r24", "r36", "r67", "r68", "r71", "r76", "r77", "r81", "r82", "r83", "r85", "r90", "r91", "r92", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r186", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Historical earnings" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Schedule of Share Based Compensation Arrangement by Share Based Payment Award Options Vested [Table Text Block]", "terseLabel": "Schedule of options vested" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested in Period", "terseLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r20", "r21", "r22", "r23", "r39", "r40", "r41", "r42", "r48", "r50", "r66", "r86", "r113", "r115", "r151", "r152", "r153", "r167", "r168", "r183", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r39", "r40", "r41", "r66", "r203" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r113", "r115", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r36", "r84", "r85", "r186", "r200" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets", "http://www.burzynskiresearch.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ECONOMIC DEPENDENCY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r35", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r115", "r116", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "ECONOMIC DEPENDENCY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureEconomicDependency" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants or Rights Fair Value", "terseLabel": "Fair value of vested warrants at date of grant" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r54", "r59" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r52", "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r236": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r237": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r238": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r239": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r240": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r241": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" } }, "version": "2.1" } ZIP 37 0001558370-22-010716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-010716-xbrl.zip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end